Continuous infusion of sepantronium bromide has also been found to induce tumor regression and intratumoral survivin suppression in established human hormone refractory prostate cancer (HRPC), non-Hodgkin lymphoma (NHL), and non-small cell lung cancer (NSCLC) tumor xenografts [1–4]. This evidence concerns the gene BIRC5 and non-Hodgkin lymphoma.